home / stock / srrk / srrk quote
Last: | $7.77 |
---|---|
Change Percent: | 0.13% |
Open: | $7.62 |
Close: | $7.77 |
High: | $8.07 |
Low: | $7.62 |
Volume: | 367,145 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$7.77 | $7.62 | $7.77 | $8.07 | $7.62 | 367,145 | 07-03-2024 |
$7.63 | $8.05 | $7.63 | $8.07 | $7.58 | 526,359 | 07-02-2024 |
$8.13 | $8.29 | $8.13 | $8.56 | $8.06 | 707,845 | 07-01-2024 |
$8.33 | $8.46 | $8.33 | $8.63 | $8.17 | 4,402,973 | 06-28-2024 |
$8.36 | $7.81 | $8.36 | $8.47 | $7.57 | 1,186,192 | 06-27-2024 |
$7.84 | $7.99 | $7.84 | $8.05 | $7.64 | 914,303 | 06-26-2024 |
$8.07 | $8.37 | $8.07 | $8.42 | $8.05 | 670,606 | 06-25-2024 |
$8.41 | $8.92 | $8.41 | $9.14 | $8.22 | 1,022,941 | 06-24-2024 |
$8.45 | $8.37 | $8.45 | $8.69 | $8.26 | 4,032,014 | 06-21-2024 |
$8.3 | $8.38 | $8.3 | $8.47 | $7.95 | 1,375,375 | 06-20-2024 |
$8.49 | $8.75 | $8.49 | $8.805 | $8.31 | 950,556 | 06-19-2024 |
$8.49 | $8.75 | $8.49 | $8.805 | $8.31 | 950,556 | 06-18-2024 |
$8.78 | $9.37 | $8.78 | $9.37 | $8.61 | 1,511,721 | 06-17-2024 |
$9.45 | $9.27 | $9.45 | $9.47 | $8.86 | 896,074 | 06-14-2024 |
$9.43 | $9.88 | $9.43 | $9.88 | $9.22 | 972,032 | 06-13-2024 |
$9.39 | $10.11 | $9.39 | $10.22 | $9.1528 | 1,373,424 | 06-12-2024 |
$9.7 | $9.53 | $9.7 | $9.87 | $9.15 | 730,818 | 06-11-2024 |
$9.63 | $9.27 | $9.63 | $9.65 | $8.92 | 702,932 | 06-10-2024 |
$9.51 | $9.27 | $9.51 | $9.83 | $9.2001 | 460,762 | 06-07-2024 |
$9.43 | $9.81 | $9.43 | $9.95 | $9.37 | 557,797 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Scholar Rock Holding Corporation Company Name:
SRRK Stock Symbol:
NASDAQ Market:
Scholar Rock Holding Corporation Website:
2024-06-13 08:00:15 ET Etzer Darout from BMO Capital issued a price target of $31.00 for SRRK on 2024-06-13 07:24:00. The adjusted price target was set to $31.00. At the time of the announcement, SRRK was trading at $9.39. The overall price target consensus is at $28.50 ...
Promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patients Analysis of baseline biomarker data in clear cell renal cell carcinoma (ccRCC) patients reveals a doubling of the ORR highlighting a potential patient selection strategy ...
- Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3 rd , at 1:50 p.m CDT/2:50 p.m. EDT - Company will host conference call to discuss the data on Tuesday, June 4 th at 7:00 a.m. CDT/8:00 a.m. EDT Scholar Rock (NASDA...